SCHEMBL5723308

SCHEMBL5723308

CSc1ccc(-c2ccccc2CO)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
PDCD1 Q15116 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
SLC6A4 P31645 4/20 0.42
SLC6A2 P23975 3/20 0.42
SLC6A3 Q01959 3/20 0.42
PDK2 Q15119 1/20 0.42
PTGS2 P35354 3/20 0.41
PTGS1 P23219 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.40
DPP4 P27487 1/20 0.39
NPC1 O15118 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR2A P28223 1/20 0.38
KCNH2 Q12809 1/20 0.38
KMT2A Q03164 1/20 0.38
TBXA2R P21731 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8604577 0.85 FFAR1 (0.50) FFAR1FFAR4PDCD1CD274SLC6A4
SCHEMBL9934396 0.85 FFAR1 (0.49) FFAR1FFAR4SLC6A4SLC6A2SLC6A3
SCHEMBL812762 0.78 PDCD1 (0.57) FFAR1FFAR4PDCD1CD274PDK2
SCHEMBL6247727 0.77 PTGS2 (0.57) FFAR1FFAR4PTGS2PTGS1NPC1
SCHEMBL7951583 0.77 PDCD1 (0.61) PDCD1CD274PDK2APOBEC3GLTB4R2
SCHEMBL117091 0.77 PDCD1 (0.65) PDCD1CD274PDK2APOBEC3GLTB4R2
SCHEMBL30826353 0.77 PDCD1 (0.65) PDCD1CD274PDK2APOBEC3GLTB4R2
SCHEMBL8441433 0.76 ALDH1A1 (0.58) FFAR1FFAR4PTGS2PTGS1
SCHEMBL27460927 0.76 SLC6A4 (0.65) SLC6A4SLC6A2SLC6A3APOBEC3GKMT2A
SCHEMBL3628757 0.75 ABL1 (0.54) PDCD1CD274PDK2APOBEC3GDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406609-B1 SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2006-09-06 EP disclosed
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2005-03-17 US disclosed
US-6825185-B2 IMPROVING THE CARDIOVASCULAR PROFILE OF A COX-2 SELECTIVE INHIBITOR BY ADMINISTERING WITH 3-HYDROXY-3- METHYLGLUTARYL COENZYME A, AN ANTIPLATELET AGENT, A THROMBIN INHIBITOR OR A THROMBOXANE INHIBITOR NITROMED, INC. 2004-11-30 US disclosed
US-20040116431-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2004-06-17 US disclosed
US-6706724-B2 ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETIC AGENT NITROMED, INC. 2004-03-16 US disclosed
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications NICOX S.A. (FR) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGES, PTGER4, PTGS1 FFAR1 387/4885FFAR4 127/4885PDCD1 4075/4885
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications PTGS2, PTGES2, PTGES FFAR1 572/4885FFAR4 268/4885PDCD1 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.